Skip to main content
. 2020 Jun 15:pvaa064. doi: 10.1093/ehjcvp/pvaa064

Table 1.

Demographic and clinical characteristics of the patients of the included studies

Study (month year) Country No. of patients Age (median, years) Sex males HTN DM Other comorbidities ACEI/ARB usage
Meng et al. (March 2020) China 417 64.5* (IQR = 55.8–69.0) 24* 42† 6*

  • CHD: 8*

  • Hypothyroidism: 1*

  • AV block: 1*

 17*
Richardson et al. (April 2020) USA 5700 63 (IQR = 52–75) 3437 3026 1808

  • CAD: 595

  • HF: 371

  • Asthma: 479

  • COPD: 287

  • CKD: 268

  • ESRD: 186

 413‡
Li et al. (April 2020) China 1178 55.5 (IQR = 38–67) 545 362 203

  • CVD: 95

  • CHD: 103

  • HF: 21

  • CKD: 44

 115*
Liu et al. (March 2020) China 511 65.2 (mean) (SE = 10.7)* 43* 78 NA NA 22*
Zhang et al. (April 2020) China 3430 57 (IQR = 45–65) 1675 1128 388

  • CHD: 178

  • CVD: 50

  • CKD: 52

  • COPD: 19

 188*
Feng et al. (April 2020) China 476 53 (IQR = 40–64) 271 113 49

  • CD: 38

  • CVD: 17

 33*
Guo et al. (March 2020) China 187 58.50 (mean) (SD = 14.66) 91 61 28

  • CHD: 2

  • CKD: 6

 19
Bean et al. (April 2020) UK 205 62.95 (mean) (SD = 19.94) 106 105 62 CAD/HF: 30 46
Yang et al. (April 2020) China 251 66 (IQR = 61–73)* 62* 126 55

  • RD: 12

  • KD: 4

  • CD: 35

 43
Zeng et al. (April 2020) China 274 60 (mean) (SD = 15) 150 75 42

  • COPD: 15

  • CKD: 5

  • CD: 31

  • CVD: 22

 28*
Ip et al. (April 2020) USA 3017 NA NA 1584 NA NA 460
Yan et al. (April 2020) China 49 277 48.75§ (mean) (SD = 14.19) 311§ 137 60 CD/CVD: 16 58
Mancia et al. (May 2020) Italy 37 031 68 (mean) (SD = 13) 23 329 NA NA

  • CD: 8570

  • RD: 2367

  • KD: 1129

 15 375
Mehra et al. (May 2020) Asia, Europe, North America 8910 49 (mean) (SD = 16) 5346 2346 1272 COPD: 225 1326
Reynolds et al. (May 2020) USA 12 594 49 (IQR = 34 –63) 5226 4357 2271

  • Prior MI: 524

  • HF: 784

  • CKD: 1214

  • COPD: 1833

 1110
Dauchet et al. (May 2020) France 288** NA 179 105†† 40

  • RD: 31

  • KD: 9

  • CD: 48

 62‡‡

HTN, hypertension; DM, diabetes mellitus; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range; CHD, coronary heart disease; AV block, atrioventricular block; CAD, coronary artery disease; HF, heart failure; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVD, cerebrovascular disease; SE, standard error; NA, not applicable; CD, cardiovascular disease; SD, standard deviation; RD, respiratory disease; KD, kidney disease, MI, myocardial infarction.

*

Reported for hypertensive patients.

†

Nine out of total 51 hypertensive patients were excluded in subsequent analysis because they were not on any antihypertensive drugs during hospitalization.

‡

Home medication reconciliation information was available for 2411 of the 2634 patients who were discharged or who died by the study end.

§

Calculated for 610 COVID 19 patients out of total of 49 277.

Patients tested for COVID-19.

**

Patients aged over 35 years suspected of or diagnosed with COVID-19.

††

Patients on antihypertensive treatment.

‡‡

Reported for COVID-19-positive patients (187 out of 288 suspected of or diagnosed patients).